The Prostate Health Index (phi ) Can Help Reduce Unnecessary Prostate BiopsiesThe Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. If you've recently been screened for Prostate Cancer and learned you have an Elevated PSA, click the button below to find out if you're a candidate for the Prostate Health Index
|
Watch Gary's Story About His Elevated PSA
|
Prostate Health Index Patient Selection Criteria
Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4)
The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (5)
Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4)
The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (5)
|
Physician Orders
If you are physician, click the Order Test button below to begin offering this test to patients in your practice.
|
Patient Orders
You can initiate an order through our physician network by clicking the order test button below or calling 855-420-7140
Or, download our Patient Physician Discussion Guide to take to your next appointment.
|
Welcome to Gary's Education Center Where You Will Find Helpful Information About Prostate Cancer & Prostate Cancer Screening
Who Should be Screened for Prostate Cancer?
The American Cancer Society recommends prostate cancer screening beginning at age 50 in men who are at average risk. Men who have above average risk for Prostate Cancer should start screening at age 45. This includes African Americans and men who have a first-degree relative (father, brother, or son) diagnosed with prostate cancer younger than age 65. For men at even higher risk (more than one first-degree relative who had prostate cancer at an early age) should be screened at Age 40. What is a PSA Test? PSA stands for Prostate Specific Antigen and is a protein made only by the prostate gland. Very little PSA is found in the blood of a man with a healthy prostate. A low PSA is better for prostate health. A rapid rise in PSA may be a sign that something is wrong. One possible cause of a high PSA level is benign (non-cancer) enlargement of the prostate. Inflammation of the prostate, called prostatitis is one more common cause of high PSA levels.(6) If you have an elevated PSA, The Prostate Health Index (phi) can help differentiate prostate cancer from benign prostate conditions. |
What Benign Conditions Can Cause Elevated PSA?
In addition to prostate cancer, a number of benign (not cancerous) conditions can cause a man's PSA level to rise. The most frequent benign prostate conditions that cause an elevation in PSA level are prostatitis (inflammation of the prostate) and benign prostatic hyperplasia (BPH) (enlargement of the prostate (6) What are the Signs & Symptoms of Prostate Cancer? Early prostate cancer usually causes no symptoms, which is why it's so important to get screened. According the American Cancer Society (7) more advanced prostate cancers sometimes cause symptoms, such as:
|
References
- Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655.
- Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169
- Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol 2014;2(4):343-350
- Lepor A, Catalona WJ, Loeb S. The Prostate Health Index: Its Utility In Prostate Cancer Detection. The Urologic Clinics of North America. 2016;43(1):1-6.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2018 – April 5, 2018
- https://www.cancer.gov/types/prostate/psa-fact-sheet (Accessed 4.20.19)
- https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html (Accessed 4.2.0.19)
